5180,71780,71780,84987,7249,6768,4828,1558,15520192020202120192020202186,2419,27020222022Analysis of pharmaceutical businessAnalysis of other businessesProduct nameBlood-flow accelerative/skin moisturizing agent HirudoidHuman anti-human IL-31 receptor A monoclonal antibody Mitchga SyringesPrimary axillary hyperhidrosis treatment agent Rapifort WipesMaruho Report 2023ReasonDrug price revisionsProvision of new treatment methodsContinuous provision of new treatment methodsChange insalesDown78,760UpUp7,416Net sales2018Net sales(Millions of yen)2018Results in the fiscal year ended September 2023Japan’s prescription drug market showed a gradual recovery trend despite the impact of COVID-19 due mainly to increases in sales of anticancer drugs and immunosuppressive agents. In addition, the springs, medical devices and components, and machinery industries, which correspond to our other businesses, were affected by soaring prices of materials and parts. As a result, net sales for the fiscal year increased 0.8% from the previous fiscal year to 96,184 million yen. We recorded operating profit of 6,227 million yen (down 62.1% year on year), ordinary profit of 6,967 million yen (down 53.7%), and profit attributable to owners of parent of 3,866 million yen (down 51.5%).5. Financial/Company Information Business Performance and Financial AnalysisWith regard to the businesses of Maruho Hatsujyo Kogyo Co., Ltd., etc., net sales of the springs, medical devices and components, and machinery businesses were 10,060 million yen (up 8.5% from the previous fiscal year), achieving over 10,000 million yen for the first time, with operating loss of 167 million yen (operating loss of 325 million yen recorded in the previous fiscal year). In the fiscal year ending September 2024, we forecast that net sales will rise by 10,600 million yen (up 5.4% year on year). This will result from winning more new orders in the springs business, assembling medical devices in the medical devices Net salesOperating lossNet salesOperating profit167million yen (158 million yen decrease in operating loss from the previous fiscal year)business, and building mass production technology for stents, standardization and unitization in the machinery business, and taking on the challenge of reforming productivity.Outlook for the fiscal year ending September 2024With atopic dermatitis, acne, hyperhidrosis, and herpes zoster (shingles) as our focus areas, we will compensate for the decline in net sales caused by drug price revisions and maintain our growth trajectory by efficiently allocating resources and carefully responding to the unmet needs of individual patients. In the fiscal year ending September 2024, we forecast net sales to increase to 98,885 million yen (up 2.8% year on year). This is because we plan to obtain additional indications for pediatric use of the antibody drug Mitchga Syringes, a treatment agent for pruritus associated with atopic dermatitis, as well as its use for prurigo nodularis, expect early market penetration, and achieve further growth in new businesses such as diagnostic drugs.(Millions of yen)86,292202310,060202386,292million yen (up 0.1% year on year)6,373million yen (down 61.9% year on year)10,060million yen (up 8.5% year on year)Business performance
元のページ ../index.html#52